Medical Discoveries | Pharma Voice | Experimental | Safety Innovations | Certifications & Approvals | Laboratories
Vials maker Stevanto plans IPO as coronavirus vaccine companies clamor for packaging: Reuters
FDA waves through a third Sarepta DMD drug, once again based on questionable biomarker data
Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktail
Novo Nordisk re-engages comedian Billy Gardell for branded Ozempic campaign
Rocket Pharma spurs more buildings and landmarks to light up for Rare Disease Day
Fierce Pharma Asia—Daiichi Sankyo’s new R&D head; Clover’s $230M raise; Insilico’s AI breakthrough
Three-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real world data back first vaccine
Ready to square off with Pfizer in next-gen pneumococcal vaccines, a Merck exec says competition’s a good thing
Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.
Novo Nordisk plots $82M tablet capacity upgrade for diabetes blockbuster-to-be Rybelsus
The global pandemic promised a windfall for forward-thinking companies making products to help combat the spread of the coronavirus. Count the Stevanto Group, one of
Sarepta Therapeutics has pushed its third Duchenne muscular dystrophy drug across the FDA finish line with controversial biomarker data—and this time without the regulatory drama.
As U.S. officials look to ramp up COVID-19 vaccinations heading into March, they’re not overlooking another pandemic-fighting tool. Eli Lilly on Friday scored a government
Actor and comedian Billy Gardell is definitely in the zone. The Type 2 diabetes health zone, that is. And he’s taking his good health to
How does an orphan drug pharma company with offices in the Empire State Building amplify rare disease awareness? Ask Rocket Pharmaceuticals. The rare disease specialist
Amid a big cancer push, Daiichi Sankyo lured Kite Pharma exec Ken Takeshita to lead its R&D work. China’s Clover Biopharmaceuticals secured $230 million in
Wayra and GE Healthcare have launched an accelerator programme across the Europe, the Middle East and Africa (EMEA) region to support digital health start-ups to
Dublin-based clinical trials group ICON is set to acquire rival contract research organisation (CRO) PRA Health Sciences in a deal worth approximately $12bn. The deal
GlaxoSmithKline (GSK) has reported Phase II results for its investigational monoclonal antibody otilimab in hospitalised COVID-19 patients – and the data is mixed. The primary
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients. NICE’s draft
